Abstract:Autoimmune hepatitis (AIH) is a chronic inflammation of the liver caused by an abnormal autoimmune reaction against hepatocytes. The pathogenesis of AIH involves a loss of tolerance to hepatic self antigens in a susceptible host. The diagnosis is based on histological abnormalities, and characteristic clinical and biochemical findings, which include abnormal levels of serum globulins, and the presence of one or more characteristic autoantibodies such as ANA, SMA, and anti-SLA. Interface hepatitis with abundant plasma cells in the infiltrate is characteristic histological features of AIH. Although the prevalence data are scare, AIH has emerging as major course of non-viral chronic hepatitis in China. More and more liver centers launch liver biopsy and serum autoantibody detection regularly. Alertness and awareness of hepatologists and histologic physicians on histologic features of AIH contributes to more and more AIH patients diagnosed in our clinics who were considered as cryptogenic chronic hepatitis previously. The simplified criteria have high sensitivity and specificity for diagnosis of AIH in Chinese patients. The revised original criteria have the complementary role to avoid the false negative diagnosis in atypical AIH patients. Immunosuppressive treatment can attenuate hepatic inflammation, revert fibrosis, and eventually improve the patient’s prognosis and life quality. Corticosteroids, either alone or in combination with azathioprine, are the standard treatment of choice for AIH. Most Chinese patients with AIH show a good response to immunosuppressive treatment, although patients with late-stage or severe disease are less likely to achieve remission. Liver transplantation is the last choice for AIH patients with decompensated end-stage disease. Transfer of regulatory immune cells such as regulatory T cells may become a potential therapy in the near future.

Emphasizing the Clinical Research of Autoimmune Liver Disease in Chinese

A Serum Metabolomic Analysis for Diagnosis and Biomarker Discovery of Primary Biliary Cirrhosis and Autoimmune Hepatitis.

The Diagnosis and Management of Autoimmune Liver Diseases

Clinical and immunological features of patients with autoimmune hepatic disease

Advances in Studies on Immunopathogenesis of Autoirmnune Liver Disease

Epidemiologic and Clinical Analysis of Non-viral Liver Diseases

Research advances in autoimmune liver diseases in 2016

Epigenetics of Autoimmune Liver Diseases: Current Progress and Future Directions

[The Management of Autoimmune Liver Diseases: from the Consensus to the Guideline].

Significance of Clinical Pathology in Diagnosis and Treatment of Autoimmune Liver Diseases

Basic and clinical progress in autoimmune liver disease

The emerging importance of autoimmune hepatitis in China

[Research Advances of Autoimmune Liver Diseases in 2018].

Exploring the Pathogenesis of Autoimmune Liver Diseases from the Heterogeneity of Target Cells

Innovative pharmacotherapy for hepatic metabolic and chronic inflammatory diseases in China

Advances in Diagnosis and Treatment of Autoimmune Liver Diseases Overlap Syndrome

Autoimmune Hepatitis in the Asia-Pacific Area

Molecular Mechanisms of Hepatobiliary and Pancreatic Diseases in Patients with Inflammatory Bowel Disease

Advances in the Pathogenesis of Autoimmune Hepatitis and New Targets for Clinical Intervention

Analysis of the clinical features in patients with autoimmune liver disease in Southwest China

Research Progress of Chinese Medicine in Treating Chronic Liver Disease by Regulating Autophagy